Dr. Reddy’s invests $620 mn in Swiss arm to acquire Haleon’s Nicotinell portfolio

Dr. Reddy’s invests $620 mn in Swiss arm to acquire Haleon’s Nicotinell portfolio

September 28, 2024 – Generic drugmaker Dr. Reddy’s Laboratories as part of its proposed acquisition of British firm Haleon’s global portfolio of consumer healthcare brands in the nicotine replacement therapy category outside of the U.S. has invested $620 million in a Swiss subsidiary.

Source: The Hindu (Link to full article)

About the author

Amitabh Arora

Amitabh Arora

Amitabh Arora has more than 18 years of experience promoting foreign direct investments (FDI), trade and economic relations between India and Switzerland, South Korea, United Kingdom and Canada. He is currently working as Director Key Accounts at the Greater Geneva Berne area (GGBa), the economic development agency of western Switzerland. GGBa offers a comprehensive range of services at no charge to foreign companies seeking to establish a presence in Switzerland. He is also the founder of FDITracker.com, tracking FDI developments worldwide. Amitabh has a Masters in International Business from the Indian Institute of Foreign Trade (IIFT) and a Bachelor of Business Studies (BBS) from College of Business Studies, India.

    Leave a Reply